Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSENTW)

Drug Name
NJH395 Drug Info
Indication
Disease Entry ICD 11 Status REF
HER2-positive metastatic breast cancer 2C60-2C65 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMSENTW

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Not Available [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Erbb2 tyrosine kinase receptor (HER2) DTT ERBB2 6.226 7.169 7.196 6.397
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease HER2-positive metastatic breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Erbb2 tyrosine kinase receptor (HER2) DTT ERBB2 5.67E-03 -1.26 -2.05
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03696771) Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer. U.S. National Institutes of Health.